Tomas Kalincik, Head of the Clinical Outcomes Research Unit at the University of Melbourne, explains his research comparing hematopoietic stem cell transplantation (HSCT) with existing treatments in relapsing and progressive MS.
Senaste avsnitt
00:00
-00:00